Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
CHINOOK THERAPEUTICS, INC. | Chief Commercial Officer | Restricted Stock (RSU)(Common Stock) | 40K | $932K | $23.30 | Feb 28, 2023 | Direct |
Kalaris Therapeutics, Inc. | President and Chief Executive Officer, Director | Stock Option (Right to Buy) | 287K | Apr 10, 2025 | Direct | ||
CHINOOK THERAPEUTICS, INC. | Chief Commercial Officer | Restricted Stock Units | 0 | Aug 11, 2023 | Direct | ||
CHINOOK THERAPEUTICS, INC. | Chief Commercial Officer | Stock Option (Right to Buy) | 0 | $26.12 | Aug 11, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KLRS | Kalaris Therapeutics, Inc. | Apr 10, 2025 | 1 | $0 | 4 | Apr 11, 2025 | President and Chief Executive Officer, Director |
KLRS | Kalaris Therapeutics, Inc. | Mar 18, 2025 | 1 | $0 | 4 | Mar 18, 2025 | President and Chief Executive Officer, Director |
KLRS | Kalaris Therapeutics, Inc. | Mar 18, 2025 | 0 | $0 | 3 | Mar 18, 2025 | President and Chief Executive Officer Exhibit 24.1 - Power of Attorney, Director |
KDNY | CHINOOK THERAPEUTICS, INC. | Aug 11, 2023 | 2 | -$2.91M | 4 | Aug 11, 2023 | Chief Commercial Officer |
KDNY | CHINOOK THERAPEUTICS, INC. | Feb 28, 2023 | 2 | $0 | 4 | Mar 2, 2023 | Chief Commercial Officer |
KDNY | CHINOOK THERAPEUTICS, INC. | Feb 15, 2023 | 0 | $0 | 3 | Feb 16, 2023 | Chief Commercial Officer |